Homology modeling and substrate binding study of human CYP2C9 enzyme

The CYP2C subfamily of human liver P450 isozymes is of major importance in drug metabolism. The most abundant 2C isozyme, CYP2C9, regioselectively hydroxylates a wide variety of substrates. A major obstacle to understanding this specificity in human CYP2C9 is the absence of a 3D structure. A 3D model of CYP2C9 was built, assessed, and used to characterize explicit enzyme‐substrate complexes using methods previously developed in our laboratory. The 3D model was assessed by determining its stability to unconstrained molecular dynamics and by comparison of specific properties with those of known protein structures. The CYP2C9 model was then used to characterize explicit enzyme complexes with three structurally and chemically diverse substrates: (S)‐naproxen, phenytoin, and progesterone. Each substrate was found to bind to the enzyme with a favorable interaction energy and to remain in the binding site during unconstrained molecular dynamics. Moreover, the mode of binding of each substrate led to calculated preferred hydroxylation sites consistent with experiment. Binding‐site residues identified for the models included Arg 105 and Arg 97 as key cationic residues, as well as Asn 202, Asp 293, Pro 101, Leu 102, Gly 296, and Phe 476. Site‐specific mutations are proposed for further integrated computational and experimental study. Proteins 1999;37:176–190. ©1999 Wiley‐Liss, Inc.

[1]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[2]  H. Yamazaki,et al.  Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. , 1997, Archives of biochemistry and biophysics.

[3]  A. Fulco,et al.  Involvement of a single hydroxylase species in the hydroxylation of palmitate at the ω—1, ω—2 and ω—3 positions by a preparation from Bacillus megaterium , 1976 .

[4]  T. Poulos,et al.  The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid , 1997, Nature Structural Biology.

[5]  P. Ortiz de Montellano,et al.  Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. , 1994, The American journal of physiology.

[6]  D. Lewis Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  J Deisenhofer,et al.  Structure and function of cytochromes P450: a comparative analysis of three crystal structures. , 1995, Structure.

[8]  G. Loew,et al.  Homology Modeling of Horseradish Peroxidase , 1995 .

[9]  T. Kronbach,et al.  A hypervariable region of P450IIC5 confers progesterone 21-hydroxylase activity to P450IIC1. , 1991, Biochemistry.

[10]  A. Fulco,et al.  Epoxidation of unsaturated fatty acids by a soluble cytochrome P-450-dependent system from Bacillus megaterium. , 1981, The Journal of biological chemistry.

[11]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[12]  T. Richardson,et al.  A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. , 1995, Archives of biochemistry and biophysics.

[13]  T. Richardson,et al.  Alterations of the regiospecificity of progesterone metabolism by the mutagenesis of two key amino acid residues in rabbit cytochrome P450 2C3v. , 1994, The Journal of biological chemistry.

[14]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[15]  J. Goldstein,et al.  Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. , 1997, Pharmacogenetics.

[16]  P. Beaune,et al.  Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast. , 1996, Pharmacogenetics.

[17]  B. Monsarrat,et al.  Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. , 1997, Bulletin du cancer.

[18]  D. Mansuy,et al.  Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.

[19]  B. Kemper,et al.  Differential effects of mutations in substrate recognition site 1 of cytochrome P450 2C2 on lauric acid and progesterone hydroxylation. , 1994, Biochemistry.

[20]  J. Halpert,et al.  Epoxidation of arachidonic acid as an active-site probe of cytochrome P-450 2B isoforms. , 1994, Biochimica et biophysica acta.

[21]  Pei-Fung Wu,et al.  cDNA sequence analysis and mutagenesis studies on the a chain of Β-bungarotoxin from Taiwan banded krait , 1996, Journal of protein chemistry.

[22]  L. Li,et al.  Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. , 1998, Archives of biochemistry and biophysics.

[23]  O. Stiffelman,et al.  Computer modeling of 3D structures of cytochrome P450s. , 1996, Biochimie.

[24]  K Chiba,et al.  Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.

[25]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[26]  P. Lu,et al.  Heme-coordinating analogs of lauric acid as inhibitors of fatty acid omega-hydroxylation. , 1997, Archives of biochemistry and biophysics.

[27]  O. Pelkonen,et al.  Role of Environmental Factors in the Pharmacokinetics of Drugs: Considerations with Respect to Animal Models, P-450 Enzymes, and Probe Drugs , 1994 .

[28]  S. Kitareewan,et al.  Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.

[29]  E. Sellers,et al.  Drug Kinetics and Alcohol Ingestion , 1978, Clinical pharmacokinetics.

[30]  J. Goldstein,et al.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.

[31]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[32]  J. Peterson,et al.  Mechanism‐based probes of the topology and function of fatty acid hydroxylases , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  K. Suslick,et al.  Shape selective alkane hydroxylation by metalloporphyrin catalysts , 1987 .

[34]  G. Loew,et al.  Prediction of Regiospecific Hydroxylation of Camphor Analogs by Cytochrome P450cam , 1995 .

[35]  D. Greenblatt,et al.  Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.

[36]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[37]  L. Pedersen,et al.  Identification of Residues 99, 220, and 221 of Human Cytochrome P450 2C19 as Key Determinants of Omeprazole Hydroxylase Activity (*) , 1996, The Journal of Biological Chemistry.

[38]  G H Loew,et al.  Construction of a 3D model of cytochrome P450 2B4. , 1997, Protein engineering.

[39]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[40]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[41]  K. Korzekwa,et al.  Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. , 1994, Cancer research.

[42]  T. Baillie,et al.  Binding of flexible ligands to proteins: Valproic acid and its interaction with cytochrome P450cam , 1993 .

[43]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[44]  J. Kerr Bond Dissociation Energies by Kinetic Methods , 1966 .

[45]  S. Wrighton,et al.  Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation , 1997, European Journal of Clinical Pharmacology.

[46]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[47]  B C Finzel,et al.  Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. , 1986, Biochemistry.

[48]  K. Griffin,et al.  Role of the peroxisome proliferator‐activated receptor in cytochrome P450 4A gene regulation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  D. Lewis,et al.  The CYP2 family: models, mutants and interactions. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[50]  S. Adams,et al.  The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin , 1997, Clinical pharmacology and therapeutics.

[51]  Roland L. Dunbrack,et al.  Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. , 1997, Journal of molecular biology.

[52]  J. Miners,et al.  Allelic and functional variability of cytochrome P4502C9. , 1997, Pharmacogenetics.

[53]  T. Richardson,et al.  Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. , 1998, Biochemistry.

[54]  J. Goldstein,et al.  Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. , 1996, The Journal of biological chemistry.

[55]  P. Ortiz de Montellano,et al.  Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. , 1998, Biochemistry.

[56]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[57]  T. Shimada,et al.  Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. , 1992, Cancer research.

[58]  P. Ortiz de Montellano,et al.  The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids. , 1988, The Journal of biological chemistry.

[59]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[60]  T. Richardson,et al.  Characterization of a cDNA encoding a human kidney, cytochrome P-450 4A fatty acid omega-hydroxylase and the cognate enzyme expressed in Escherichia coli. , 1993, Biochimica et biophysica acta.

[61]  T. Richardson,et al.  Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[62]  P. Ortiz de Montellano,et al.  Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. , 1984, The Journal of biological chemistry.

[63]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[64]  G. Loew,et al.  Refinement of 3D models of horseradish peroxidase isoenzyme C: Predictions of 2D NMR assignments and substrate binding sites , 1996, Proteins.

[65]  T. Aoyama,et al.  Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.

[66]  P. Lu,et al.  Heteroatom Substitution Shifts Regioselectivity of Lauric Acid Metabolism from ω-Hydroxylation to (ω-1)-Oxidation , 1995 .

[67]  C. Breneman,et al.  Determining atom‐centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis , 1990 .

[68]  P. Ortiz de Montellano,et al.  Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. , 1994, The Journal of pharmacology and experimental therapeutics.

[69]  C. Sander,et al.  Quality control of protein models : directional atomic contact analysis , 1993 .

[70]  T. Edeki,et al.  Genetic polymorphism of S-mephenytoin 4'-hydroxylation. , 1996, Psychopharmacology bulletin.

[71]  S. Imaoka,et al.  Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase. , 1993, The Journal of pharmacology and experimental therapeutics.

[72]  J. Miners,et al.  Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[73]  B. Masters,et al.  20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. , 1993, Circulation research.

[74]  S. Imaoka,et al.  Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid omega-hydroxylase expressed in human kidney. , 1993, DNA and cell biology.

[75]  R. Tukey,et al.  Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. , 1996, Biochemical pharmacology.

[76]  P. Lu,et al.  Fatty acid discrimination and omega-hydroxylation by cytochrome P450 4A1 and a cytochrome P4504A1/NADPH-P450 reductase fusion protein. , 1995, Archives of biochemistry and biophysics.

[77]  D. Hi,et al.  Genetic polymorphism of S-mephenytoin 4'-hydroxylation. , 1996, Psychopharmacology bulletin.

[78]  J. Miners,et al.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.

[79]  A. Simpson The cytochrome P450 4 (CYP4) family. , 1997, General pharmacology.

[80]  J. Halpert,et al.  Structural determinants of progesterone hydroxylation by cytochrome P450 2B5: the role of nonsubstrate recognition site residues. , 1998, Archives of biochemistry and biophysics.

[81]  R. Estabrook,et al.  Cytochrome P450 and the arachidonate cascade 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  D. Mansuy,et al.  Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. , 1996, European journal of biochemistry.

[83]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[84]  C. Sander,et al.  Database algorithm for generating protein backbone and side-chain co-ordinates from a C alpha trace application to model building and detection of co-ordinate errors. , 1991, Journal of molecular biology.

[85]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an NMR study. , 1997, Biochemistry.

[86]  M. Wester,et al.  Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. , 1998, Archives of biochemistry and biophysics.

[87]  J Deisenhofer,et al.  Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution. , 1994, Journal of molecular biology.

[88]  C. Miranda,et al.  The regiospecific hydroxylation of lauric acid by rainbow trout (Oncorhynchus mykiss) cytochrome P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[89]  E. Gillam,et al.  Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. , 1997, Chemical research in toxicology.

[90]  Roland L. Dunbrack,et al.  Conformational analysis of the backbone-dependent rotamer preferences of protein sidechains , 1994, Nature Structural Biology.

[91]  R. Levy Phenytoin: biopharmacology. , 1980, Advances in neurology.

[92]  D. Shen,et al.  Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[93]  T. Poulos,et al.  Modeling protein-substrate interactions in the heme domain of cytochrome P450(BM-3). , 1994, Acta crystallographica. Section D, Biological crystallography.

[94]  M. Waterman,et al.  The role of cytochrome b5 in the biosynthesis of androgens by human P450c17. , 1995, Archives of biochemistry and biophysics.

[95]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[96]  M. Komori,et al.  Different mechanisms of regioselection of fatty acid hydroxylation by laurate (omega-1)-hydroxylating P450s, P450 2C2 and P450 2E1. , 1994, Journal of Biochemistry (Tokyo).

[97]  T. Poulos,et al.  Structure of cytochrome P450eryF involved in erythromycin biosynthesis , 1995, Nature Structural Biology.

[98]  J. Miners,et al.  Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. , 1996, Methods in enzymology.

[99]  H. Yamazaki,et al.  Formation in vitro of an inhibitory cytochrome P450 x Fe2+-metabolite complex with roxithromycin and its decladinosyl, O-dealkyl and N-demethyl metabolites in rat liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[100]  Manfred J. Sippl,et al.  Boltzmann's principle, knowledge-based mean fields and protein folding. An approach to the computational determination of protein structures , 1993, J. Comput. Aided Mol. Des..

[101]  A. Fulco,et al.  ω-1, ω-2 and ω-3 Hydroxylation of long-chain fatty acids, amides and alcohols by a soluble enzyme system from Bacillus megatyerium , 1975 .

[102]  P. D. de Montellano,et al.  The Catalytic Site of Cytochrome P4504A11 (CYP4A11) and Its L131F Mutant* , 1998, The Journal of Biological Chemistry.

[103]  F. Berthou,et al.  Evidence that cytochrome P450 2E1 is involved in the (omega-1)-hydroxylation of lauric acid in rat liver microsomes. , 1994, Biochemical and biophysical research communications.

[104]  H. Yamazaki,et al.  Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[105]  B. Rost,et al.  Combining evolutionary information and neural networks to predict protein secondary structure , 1994, Proteins.

[106]  H. Yamazaki,et al.  Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. , 1997, Pharmacogenetics.